NASDAQ:AURA Aura Biosciences Q1 2025 Earnings Results & Report $6.10 -0.24 (-3.79%) Closing price 04:00 PM EasternExtended Trading$6.11 +0.01 (+0.16%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aura Biosciences missed analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.55 versus the -$0.47 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 15, 2025TimeBefore Market OpensConference Call6:00 AM ET Aura Biosciences EPS ResultsActual EPS-$0.55Consensus EPS -$0.47Beat/MissMissed by -$0.08One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersAura Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAura Biosciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aura Biosciences Q1 2025 Earnings FAQ Did Aura Biosciences beat earnings estimates for Q1 2025? Aura Biosciences (NASDAQ:AURA) reported earnings of -$0.55 per share for Q1 2025, missing the consensus estimate of -$0.47. The report was announced on Thursday, May 15, 2025. When is Aura Biosciences' next earnings date? Aura Biosciences' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aura Biosciences on the company's earnings history page. Aura Biosciences Earnings HeadlinesAura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry IndexSeptember 21, 2026 | marketscreener.comMAura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.October 16 at 1:00 AM | Brownstone Research (Ad)Aura Biosciences to Participate in Upcoming Investor ConferenceSeptember 2, 2026 | globenewswire.comAura Biosciences Grants Inducement Equity Awards to Newly Appointed ExecutivesSeptember 1, 2026 | quiverquant.comQAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comSee More Aura Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email. Email Address About Aura BiosciencesAura Biosciences (NASDAQ:AURA) is a clinical-stage biotechnology company focused on developing precision oncology therapies that selectively target and destroy cancer cells while preserving surrounding healthy tissue. The company’s technology platform uses tumor-targeting virus-like particles and light-activated compounds to deliver localized anticancer treatment. Aura’s lead product candidate is belzupacap sarotalocan, also known as AU-011, an investigational therapy designed for the treatment of primary choroidal melanoma, a rare cancer of the eye. AU-011 is administered locally and activated with near-infrared light, with the goal of treating tumors while reducing damage to vision-preserving ocular structures. The company has also evaluated the platform’s potential applications in other solid tumors. Aura Biosciences was founded in 2009 and is headquartered in Cambridge, Massachusetts. The company’s research and clinical development activities are focused on oncology, with clinical programs involving specialized medical centers and patients in multiple regions. Elisabet de los Pinos, Ph.D., the company’s founder, serves as chief executive officer.View Aura Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
